Pfizer/Seagen: FTC Explores Innovation Theory of Harm It Examined In 2009 Wyeth Acquisition

In criticizing the FTC’s review of Pfizer’s (PFE) proposed buyout of Seagen (SGEN), Albert Bourla, CEO of the New York pharmaceutical giant, said last week that the agency was straying from the mainstream of antitrust enforcement by examining whether the $43 billion deal would thwart industry innovation. But this isn’t the first time the agency […]